Stocks · News reference
Ardelyx (NASDAQ:ARDX) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced results from
A securities class action lawsuit has been filed against Ardelyx, Inc. for allegedly providing misleading statements about its commercial performance while concealing material adverse facts regarding payer access barriers and reimbursement issues for XPHOZAH and IBSRELA. The company reduced its 2026 IBSRELA revenue guidance and withdrew long-term XPHOZAH guidance on August 6, 2026, causing the stock to decline approximately 18% in a single day.
Wedbush analyst Laura Chico reiterates Ardelyx (NASDAQ:ARDX) with a Outperform and maintains $9 price target.